By FMTeam Emcure Pharma is a decently big name in the pharma scene of India, but unfortunately, just like some other companies that are keeping up the good work, not a lot of people know about Emcure as well. So, we’re here to properly introduce and talk about things like Emcure Pharmaceuticals Net Worth, Owner, CEO, Head Office and much more.
| Company Name | Emcure Pharmaceuticals Limited |
| Establishment Year | 1981 |
| Head Office | Pune |
| Owner/Founder | Satish R. Mehta |
| CEO Name | Satish R. Mehta, Managing Director (top executive) |
| Industry | Pharmaceuticals |
| Number of Employees | 10,000+ |
| Net Worth / Market Capitalization | About ₹25,612 crore as of 8 Nov 2025 |
| Total Revenue (2025) | ₹7,963 crore |
Company Profile
Emcure Pharmaceuticals started its road to success in 1981 when Satish Mehta established the company. For this pharma company, it all started back in 1981, but through the early years, of course, they were only the contract manufacturers, and that’s all. But then, in the 1990s, actually, the company tried its hand at manufacturing its own generics, and that worked out pretty great. Like, on the way to success, Emcure has inked a number of agreements, such as the licensing of HIV medicines in 2006 and the collaboration with Roche for affordable oncology biologics in India in 2012. Currently, their main head office is in Pune, just so you know.
Net Worth
It is true that Emcure went public in 2024; that means, now you can see a bunch of financial data about this company, though the direct net worth numbers aren’t readily available. But since it is a public company, you can have a look at the recent market cap numbers, and for Emcure, it is about 256.12 billion INR.
Recent Updates and Outlook
The recent quarterly results have demonstrated a positive trend, pretty much. How exactly? Well, we know that the company was able to increase its revenue by almost 20% year-on-year in the second quarter of fiscal year 2025, making it ₹2,002 crore. The revenue at the end of the last quarter of the fiscal year 2025 went up to ₹2,116 crore, and the profit after tax (PAT) also made a significant leap. Other than that, it is said that they have achieved better results abroad, for example, in Canada and various other new markets.